Pharma feed

AstraZeneca PLC
Investegate· 24 May 2019

Corporate, London Stock Exchange, Regulatory News Headlines Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms

  • Forecast Pte Ltd
  • AstraZeneca PLC
  • Barclays Capital
  • London Stock Exchange plc
  • Regulatory and Legal
  • Press Releases
  • Company Websites
AstraZeneca PLC
Investegate· 24 May 2019

Corporate, London Stock Exchange, Regulatory News Headlines Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLC

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms

  • Forecast Pte Ltd
  • AstraZeneca PLC
  • Jefferies LLC
  • London Stock Exchange plc
  • Regulatory and Legal
  • Press Releases
  • Company Websites
N
Merck & Co., Inc.
Mak Daily· 24 May 2019

Abner Herrman & Brock LLC Has Raised Merck & Co INC (MRK) Stake by $3.27 Million as Stock Price Rose

Investors sentiment decreased to 0.92 in Q4 2018. Its down 0.01, from 0.93 in 2018Q3. It turned negative, as 37 investors sold MRK shares while 660 reduced holdings. 157 funds opened positions while 485 raised stakes.

  • Abner Herrman & Brock LLC
  • Merck & Co., Inc.
  • Funding Activities
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Invest Tribune· 24 May 2019

Shareholder Abner Herrman & Brock LLC Boosted Merck & Co INC (MRK) Holding

Investors sentiment decreased to 0.92 in Q4 2018. Its down 0.01, from 0.93 in 2018Q3. It fall, as 37 investors sold MRK shares while 660 reduced holdings. 157 funds opened positions while 485 raised stakes. 1.94 billion shares or 3.54% more from 1.87 billion shares in 2018Q3 were reported.

  • Abner Herrman & Brock LLC
  • Merck & Co., Inc.
  • Funding Activities
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Enherald· 24 May 2019

As Merck Co. (MRK) Market Value Rose, Holder First Mercantile Trust Co Has Lowered Its Stake; Bluemar Capital Management Raised Its Zions Bancorporation N A (ZION) Position by $1.47 Million

Bluemar Capital Management Llc increased its stake in Zions Bancorporation N A (ZION) by 40% based on its latest 2018Q4 regulatory filing with the SEC. Bluemar Capital Management Llc bought 36,808 shares as the company’s stock rose 5.28% with the market.

  • First Mercantile
  • Merck & Co., Inc.
  • Zions Bancorp
  • Funding Activities
  • News Articles
  • News and Other Websites
N
Mylan Specialty LP
Operanewsnow· 24 May 2019

Global Disopyramide Phosphate Market Overview 2019-2025 : Sanofi, Merck, Teva, Santa Cruz, Mylan, Interpharm, Watson – OperaNewsNow

Market study report Titled Global Disopyramide Phosphate Market 2019 Industry Research Report recently published on e-marketresearch.com is the key document for industries/clients to understand current global competitive market status. The Disopyramide Phosphate market study report base year is 2018 and provides market research data status (2014-2018) and forecast (2019-2025) and also categorizes the Disopyramide Phosphate market into key industries, region, type and application.

  • Mylan Specialty LP
  • Merck & Co., Inc.
  • Sanofi
  • New Offerings
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
Market Trends· 24 May 2019

Global Preventable Vaccines Market 2019 – GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi – Market Trends

Report represents a comprehensive study of the Preventable Vaccines Market. It consists of growth rate for the forecast period. The global report sums up by providing the estimated development of Preventable Vaccines market in near future.

  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Novartis AG
  • Sanofi
  • New Offerings
  • News Articles
  • News and Other Websites
N
Mylan Specialty LP
Industry Reports· 24 May 2019

Innovative Report on Rivastigmine Market with Competitive Analysis, New Business Developments Growth Factors and Top Companies: Novartis, Sun Pharmaceutical, Alvogen, Mylan Pharmaceuticals, Teva, Dr.

Rivastigmine market Rivastigmine market provides a detailed analysis of the industry for the estimation period of 2019 – 2025. Rivastigmine Market by Reports Monitor report includes market size, growth rate, market share, application, future trends. The market research of Rivastigmine is precise but encloses all points in brief which are essential and relevant for a customer of Rivastigmine industry.

  • Mylan Specialty LP
  • Novartis AG
  • Sun Pharmaceutical Industries
  • Competitive Landscape
  • News Articles
  • News and Other Websites
N
Novartis AG
Pharmaphorum· 24 May 2019

EU regulators accept Novartis’ triple asthma combo

European regulators have accepted Novartis’ filing for a triple combination therapy for asthma known as QVM149, triggering payments to development partners Vectura and Sosei. QVM149 is a triple therapy consisting of indacaterol (acetate), glycopyrronium (bromide) and mometasone (furoate), which is being developed as a daily inhaled treatment for asthma delivered via the company’s Breezhaler inhaler.

  • Novartis AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Novartis AG
Market Digest· 24 May 2019

Novartis CEO sees China M&A hampered by data, regulatory standards

By using our website, you agree to the use of cookies as described in our cookie policy.

  • Novartis AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Pfizer Inc.
Market Trends· 24 May 2019

Cholesterol-Lowering Drugs Market 2019 – AstraZeneca, Merck, Pfizer, Kowa, Daiichi Sankyo – Market Trends

Report represents a comprehensive study of the Cholesterol-Lowering Drugs Market. It consists of growth rate for the forecast period. The global report sums up by providing the estimated development of Cholesterol-Lowering Drugs market in near future.

  • Daiichi Sankyo Co Ltd
  • Pfizer Inc.
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • New Offerings
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
Worldwidereport24· 24 May 2019

Global Pediatric Healthcare Market Outlook 2019-2025:-Abbott, AstraZeneca, GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, Perrigo, Mead Johnson, Nestlé, Danone, Prophylactic Products, Therapeutic Produ

Global Pediatric Healthcare Market Outlook 2019-2025:-Abbott, AstraZeneca, GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, Perrigo, Mead Johnson, Nestlé, Danone, Prophylactic Products, Therapeutic Products The global market report for the “Pediatric Healthcare Market” is a widespread report which provides both the analysis on the highly important areas and the company comprehension which is guided by the industry experts.

  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Danone SA
  • Pfizer Inc.
  • AstraZeneca PLC
  • Sanofi
  • Perrigo Company plc
  • New Offerings
  • News Articles
  • News and Other Websites
N
Illumina Inc
Stocknewsmagazine· 24 May 2019

Label-Free Detection Market Trends, Research Report With AMETEK, Illumina, Danaher Corporation, Corning Incorporated, HORIBA, GE, QIAGEN, Merck, Bio-Rad Laboratories, SRU Biosystems, X-BODY Bioscience

Global label-free detection market is expected to rise from its initial estimated value of USD 0.93 billion in 2018 to an estimated value of USD 1.68 billion by 2026, registering a CAGR of 7.7% in the forecast period of 2019-2026.

  • Illumina Inc
  • Merck & Co., Inc.
  • Qiagen GmbH
  • Danaher Corporation
  • Horiba Ltd
  • Bio-Rad Laboratories, Inc.
  • AMETEK Inc
  • New Offerings
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Market Trends· 24 May 2019

Global Polyvinylidene Difluoride (PVDF) Membrane Market Top Players 2019 – 2025 : Merck & Company, Arkema, Koch Membrane Systems – Market Trends

The Global Polyvinylidene Difluoride (PVDF) Membrane Market report focuses on volume and value at global level, regional level and company level. From a global perspective, this report represents overall Polyvinylidene Difluoride (PVDF) Membrane market size by analyzing historical data and future prospect.

  • Merck & Co., Inc.
  • New Offerings
  • News Articles
  • News and Other Websites
N
UCB SA
Industrynewsblog· 24 May 2019

Global PEGylated Proteins Market Insights & Depth Analysis: Merck Sharp & Dohme, ENZON Pharmaceuticals, Roche, Pfizer, Amgen, UCB – Industry News Blog

The global market report for the “PEGylated Proteins Market” is a widespread report which provides both the analysis on the highly important areas and the company comprehension which is guided by the industry experts. In the initial part of the report, the recent launches of the PEGylated Proteins market are given along with the in-depth information about the past statistics to implement to the present situation of the market.

  • UCB SA
  • Merck Sharp & Dohme Ltd
  • Pfizer Inc.
  • Amgen, Inc.
  • Enzon Pharmaceuticals Inc
  • New Offerings
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
Thetechnologymarket· 24 May 2019

Global Parkinson Disease Drug Market Forecast (2019-2024) : Merck, Akorn, GSK, Novartis, Boehringer Ingelheim – Technology Market

According to a new research report titled Global Parkinson Disease Drug Market 2019, the market for Parkinson Disease Drug probably is likely to indicate adequate growth during the period of analysis. The study explains the market dynamics and noteworthy factors that could have an impact on the entire forecast period for the industry.

  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Akorn, Inc.
  • Forecast Pte Ltd
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • New Offerings
  • News Articles
  • News and Other Websites
N
Celgene Corp
The Pharma Letter· 24 May 2019

BRIEF—B-MS extends expiration date for exchange offers for Celgene

Ahead of market opening, Bristol-Myers Squibb today announced the extension of the expiration date of the offers to exchange issued by Celgene Corp up to $19,850,000,000 aggregate principal amount of new notes to be issued by B-MS, as part of its planned $74 billion share and cash acquisition of the biotech major.

  • Celgene Corp
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Crypto News Today· 24 May 2019

Global Hospital-Acquired Infection Control Market Status 2019-2026 : Merck, Pfizer, 3M, Alere, Cepheid – Crypto News Today

The report on the global “Hospital-Acquired Infection Control market” studies the existing as well as the future visions of the global Hospital-Acquired Infection Control market. It includes a detailed outline of the global Hospital-Acquired Infection Control market along with market pictures.

  • Merck & Co., Inc.
  • Cepheid Inc
  • Pfizer Inc.
  • 3M Co
  • Crypto Co
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Johnson & Johnson
Market Trends· 24 May 2019

Foot Care Products Market 2019 Global Demand and Precise Outlook – Johnson & Johnson, Bayer, Blistex, Sanofi, McPherson, ProFoot – Market Trends

Global Foot Care Products Market Insights, Forecast To 2025 The Foot Care Products market report is a most important research for who looks for complete information on the Winding Wire market. The report covers all information on the global and regional markets including historic and future trends for market demand, size, trading, supply, competitors, and prices as well as global predominant vendor’s information.

  • Blistex Inc
  • Johnson & Johnson
  • Aetna Inc
  • Sanofi
  • New Offerings
  • News Articles
  • News and Other Websites
N
Pfizer Inc.
Market Reports Journal· 24 May 2019

Top Players – Pfizer, Globe Pharmaceuticals, Delta Pharma Limited, Beacon Pharmaceuticals, Drug International – Market Reports

Description -Tofacitinib is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Common side effects include diarrhea, headache, and high blood pressure. Serious side effects may include infections, cancer, and pulmonary embolism The following Key Players are covered in this report, with sales, revenue, industry share for each company: Pfizer, Globe Pharmaceuticals, Delta Pharma Limited, Beacon Pharmaceuticals, Drug International, etc.

  • Delta Pharma Inc
  • Pfizer Inc.
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
FiercePharma· 24 May 2019

FiercePharmaAsia—Shingrix's Chinese nod; Chugai's $1B R&D site; Lilly's Verzenio safety woes

GlaxoSmithKline's fast-growing Shingrix has nabbed approval in China after its drug regulator put the shot on its list of high-priority new products. Roche's Chugai is investing $1.15 billion to combine two Japanese R&D sites into a new one.

  • GlaxoSmithKline PLC
  • New Offerings
  • News Articles
  • News and Other Websites
N
AstraZeneca PLC
Market Reports Journal· 24 May 2019

Innovative Report on Olaparib Market with Competitive Analysis, New Business Developments and Top Companies: AstraZeneca, Everest Pharmaceuticals, etc – Market Reports

Innovative Report on Olaparib Market with Competitive Analysis, New Business Developments and Top Companies: AstraZeneca, Everest Pharmaceuticals, etc Olaparib Market Industrial Growth of Olaparib Market 2019-2024: The latest report added by Reports Monitor demonstrates that the global Olaparib market will showcase a steady CAGR in the coming years.

  • AstraZeneca PLC
  • Competitive Landscape
  • News Articles
  • News and Other Websites
N
Medtronic
Honest Version· 24 May 2019

3D Cardiac Mapping System Market Key Players Insights, Business Growth Statistics, Trends and Forecast 2027 – Abbott, Boston Scientific, Johnson & Johnson Services, Medtronic – Honest Version

The report on “3D Cardiac Mapping System Market” will help Major Players and the new entrants to understand scrutinize the market in detail. This information will encourage the Major Players to decide their business strategy and achieve proposed business aims.

  • Forecast Pte Ltd
  • Medtronic
  • Johnson & Johnson
  • Boston Scientific Corp
  • New Offerings
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
The Pharma Letter· 24 May 2019

With bribery fines behind it, GSK brings back bonuses for sales staff

British drugmaker GlaxoSmithKline has reintroduced its bonus program for sales staff, to “better recognise… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features,

  • GlaxoSmithKline PLC
  • New Offerings
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
Legally India· 24 May 2019

L&L acts on India leg of GSK JV with Pfizer consumer healthcare

Pfizer Inc and GlaxoSmithKline plc today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands. The Boards of Directors of both companies have unanimously approved the transaction under which Pfizer will contribute its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business.

  • GlaxoSmithKline PLC
  • Pfizer Inc.
  • Management Changes
  • Procurement and Sales
  • News Articles
  • News and Other Websites
1 2 3 4 5